Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of HR20031 tablets, which are indicated for improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin [1] Company Summary - Heng Rui Medicine (600276) announced the approval of its HR20031 tablets, which combine empagliflozin, linagliptin, and metformin [1] - The approved indication for HR20031 is to be used in conjunction with diet control and exercise for adult patients with type 2 diabetes [1] Industry Summary - The approval of HR20031 tablets reflects ongoing advancements in diabetes treatment options within the pharmaceutical industry [1] - The product aims to address the needs of patients with type 2 diabetes who struggle with blood sugar control despite existing treatments [1]